Cell Therapeutics lisofylline mucositis Phase II/III trial planned for 1997.
Executive Summary
CTI LISOFYLLINE PHASE II/III MUCOSITIS TRIAL TO BEGIN IN SECOND HALF OF 1997, Cell Therapeutics reports in a prospectus for an initial public offering. The 100-patient mucositis study will compare a 3 mg/kg dose of CTI's synthetic small molecule drug four times daily to a 6 mg/kg twice daily dose in patients with solid tumors receiving dose-intensive radiation and/or chemotherapy who are at risk for developing severe mucositis and infection. Lisofylline appears to decrease the pool of oxidizable lipids following radiation or chemotherapy, CTI said, preventing related cellular inflammatory response.